OncoSil Medical completed its Humanitarian Device Exemption (HDE) application submission to the U.S. FDA for its OncoSil device, aimed at treating distal cholangiocarcinoma (dCCA). The update is a positive regulatory milestone, though it does not by itself confirm approval or commercial timeline.
OncoSil Medical completed its Humanitarian Device Exemption (HDE) application submission to the U.S. FDA for its OncoSil device, aimed at treating distal cholangiocarcinoma (dCCA). The update is a positive regulatory milestone, though it does not by itself confirm approval or commercial timeline.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.12
